Given the role of HIF-1 as a key player for tumor angiogenesis and as part of the cellular responses to cancer treatments, it is not surprising that the status of HIF-1α overexpression correlates with poor prognosis in many cancer types (head and neck, oesophagus, pancreas, stomach, gall bladder, liver, colon, lung, pleura, breast, ovaries, uterus and bladder [71–84]). Here, HIF1A is linked to neoplasm.